share_log

BRIEF-IX Biopharma Says Entered Exclusive License Agreement With Seelos Therapeutics

reuters ·  Nov 24, 2021 14:10

Nov 24 (Reuters) - IX Biopharma Ltd IXBI.SI :

* ENTERED INTO AN EXCLUSIVE LICENSE AGREEMENT WITH SEELOS THERAPEUTICS

* WILL RECEIVE US$9 MILLION UPFRONT PAYMENT TO BE SATISFIED IN CASH AND SHARES

* ALSO ELIGIBLE FOR UP TO US$239 MILLION IN MILESTONE PAYMENTS AS PART OF DEAL

Source text for Eikon: ID:nSN4DNx5y Further company coverage: IXBI.SI

((Reuters.Briefs@thomsonreuters.com;))

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment